Bristol Myers Squibb Co $49.11

up +0.94


16/4/2014 06:40 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has outperformed the S&P 500 by 1%

Partner Headlines

  1. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo ...

    Benzinga
  2. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  3. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  4. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  5. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  6. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  7. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  8. Gilead's HCV Challengers Near The Starting Gate

    IBD
  9. Gilead's HCV Challengers Near The Starting Gate

    IBD
  10. Abbott Capturing Incremental Market Share

    GuruFocus
  11. US Stock Futures Jump Ahead Of Economic Data

    Benzinga
  12. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  13. Arrowhead Surges As Analysts Laud Hepatitis B Drug

    IBD
  14. Bristol Moving Ahead With Lung-Cancer Drug Combo

    IBD
  15. Bristol-Myers Squibb's

    IBD
  16. Pfizer Gets Good News For Pneumonia, Bone-Thinner Drugs

    IBD
  17. Market Wrap For February 24: Markets Showing Strength To Start The Week

    Benzinga
  18. FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation

    FoxBusiness
  19. Actavis, Forest In $25 Bil Deal

    IBD
  20. Actavis' Buyout Of Forest Creating Spec Pharma Giant

    IBD
  21. Vanguard Health Care Fund's Top Five

    GuruFocus
  22. UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive ...

    Benzinga
  23. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  24. Investors Brace for Bear Market

    FoxBusiness
  25. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  26. #PreMarket Primer: Monday, January 27: Markets Open The Week On Edge

    Benzinga
  27. Bristol-Myers Int'l Sales Soar

    IBD
  28. Top Earnings-Related Movers for Week of Jan. 20th

    Benzinga
  29. Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

    Benzinga
  30. Bristol Q4 Beats, But Nivolumab Still Worries Market

    IBD
  31. Stocks Open Sharply Lower; Kansas City Southern Collapses

    IBD
  32. Stock Futures Down, Off Lows; Microsoft And Juniper Climb

    IBD
  33. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  34. #PreMarket Primer: Friday, January 24: Growth Fears Drag Down Emerging ...

    Benzinga
  35. Earnings Scheduled For January 24, 2014

    Benzinga
  36. Stocks To Watch For January 24, 2014

    Benzinga
  37. Cancer drug result in question

    IBD
  38. Bristol-Myers' New Nivolumab Trial Sparks Worries

    IBD
  39. Growth Fund Of The Year: Stock Picks

    YCharts
  40. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  41. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is

    GuruFocus
  42. Ligand Pharmaceuticals Poised For Full-Year Profit

    IBD
  43. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  44. Daclatasvir Marketing Authorization Application for Treatment of Chronic ...

    Benzinga
  45. The Top Five Drug Launches Of 2013

    IBD
  46. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
  47. New Drugs Could Change Cancer Landscape In 2014

    IBD
  48. Benzinga's Top #PreMarket Losers

    Benzinga
  49. 21 Stocks Giving the Gift of Dividend Growth

    GuruFocus
  50. Benzinga's Top #PreMarket Losers

    Benzinga
Trading Center